Search

NACA Tablets Inhibit Vision Reduction in Usher Syndrome Patients

The USPTO has published a patent application (US20260083688A1) detailing compositions and methods for treating Usher syndrome associated retinitis pigmentosa using N-acetylcysteine amide (NACA) tablets. The application outlines specific dosages and claims to inhibit vision degradation and protect retinal sensitivity in patients.

Patent Application: Reversing Dexmedetomidine Sedation

The USPTO has published a patent application (US20260083689A1) detailing methods and compositions for reversing dexmedetomidine sedation using dextroamphetamine and/or lisdexamfetamine. The application was filed on October 7, 2025, by inventors Ken Solt, Oluwaseun Johnson-Akeju, and Emery N. Brown.

Patent Application for Dispersible Pharmaceutical Formulations

The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.

Patent Application for Treating Disease with Dichlorphenamide

The USPTO has published a patent application (US20260083692A1) from Strongbridge Dublin Limited for methods of treating disease using dichlorphenamide in conjunction with an organic anion transporter-1 (OAT1) substrate. The application details methods for administering the compounds and monitoring patient response and toxicity.

Intranasal Pharmaceutical Composition for Migraine Treatment

The USPTO has published a patent application (US20260083693A1) for an intranasal pharmaceutical composition containing ibuprofen and ketoprofen for treating migraine and headaches. The application details a method for manufacturing preparations with a combination of these active ingredients at reduced dosages compared to oral administration.

Composition of L-leucine and fish oil for muscle health

The USPTO has published a patent application (US20260083694A1) for a composition comprising L-leucine and fish oil, intended for muscle health and the prevention of muscle mass and strength loss. The application was filed by ABIOGEN PHARMA S.P.A.

Patent Application: Composition for Mitigating Veisalgia and Nausea

The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.

Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics

The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.

Patent Application: Composition for Controlling Aquatic Organism Infections

The USPTO has published a new patent application (US20260083697A1) from B. G. Negev Technologies and Applications Ltd. The application details a composition containing an esterified fatty acid for preventing or treating monogenean infections in aquatic organisms.

Patent Application: Synergistic Stimulation for Cystic Fibrosis Mucus Obstruction

The USPTO has published a new patent application (US20260083698A1) detailing methods for treating mucus obstruction in cystic fibrosis and other disorders. The application, filed on September 19, 2023, describes a combination therapy involving a b-adrenergic agonist or adenylate cyclase activator with a cholinergic agonist.

Patent Application for Psychoactive Medicines Treating Disorders

The USPTO has published patent application US20260083699A1 by Transcend Therapeutics, Inc. The application details psychoactive medicines, including 2C-B and cathinones, for treating psychiatric and neurological conditions. The filing date was December 4, 2025.

Patent Application for Inflammatory Condition Treatment Compositions

The USPTO has published a new patent application (US20260083701A1) for compositions and methods related to the treatment of inflammatory conditions. The application details compounds and formulations aimed at managing inflammation and associated symptoms like dryness, itching, and redness.

Patent Application: Methods Treat/Prevent Protein Aggregation Diseases Using Sulfatase Inhibitor

The USPTO has published a new patent application (US20260083700A1) detailing methods for treating and/or preventing protein-aggregation diseases by administering a sulfatase inhibitor. The application was filed on September 26, 2025, by inventors Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez.

Patent Application: Inhalation Formulation for Treating IPF Disease

The USPTO has published a patent application (US20260083702A1) detailing an inhalation formulation for treating Idiopathic Pulmonary Fibrosis (IPF) disease. The application describes formulations using specific drugs like apremilast and roflumilast, aiming to improve bioavailability and clinical efficacy compared to oral administration.

USPTO Patent Application for Indoline Derivatives as Serotonergic Agents

The USPTO has published a patent application (US20260083703A1) for indoline derivatives intended for use as serotonergic agents. The application details potential treatments for disorders related to serotonin receptor activation, including psychosis, mental illnesses, and CNS disorders.

USPTO Patent Application for Lactation Reduction Compounds

The USPTO has published a patent application (US20260083687A1) for compounds intended for reducing lactation and improving health. The application, filed on April 14, 2023, lists specific disulfide, sulfide, trisulfide, sulfone, thiosulfinate, and thiosulfonate compounds as preferred embodiments. This represents a new patent filing, not a regulatory rule or guidance.

Patent Application for Suppressing Reflux-Induced Protein Adducts

The USPTO has published patent application US20260083686A1, filed on November 24, 2025, by Alexander Zaika and Sergey I Dikalov. The application details methods and compounds for suppressing the accumulation of reflux-induced protein adducts.

Skin Barrier Film System Patent Application

The USPTO has published a new patent application, US20260083684A1, for a skin barrier film system. The application details a system comprising a film layer, adhesive, impregnated treatment, and a removable layer, designed to accommodate patient physical attributes. The filing date was September 24, 2025.

Method Uses Monoterpene or Sesquiterpene to Permeabilize Blood Brain Barrier

The USPTO has published a patent application detailing a method for permeabilizing the blood-brain barrier using monoterpenes or sesquiterpenes. The application, assigned to the University of Southern California, describes a treatment for central nervous system cancers involving perillyl alcohol and CAR-T cells.

Gear Isle Recalls Chocolate for Undeclared Sildenafil and Tadalafil

Gear Isle is voluntarily recalling its Gold Lion and ilum chocolate products nationwide due to undeclared sildenafil and tadalafil. These ingredients can interact with prescription medications and pose a serious health risk. Consumers are advised to stop using the product and return it for a refund.

Falcon Trading Company Recalls Organic Black Beans for Pesticide Residue

Falcon Trading Company, Inc. is recalling organic black beans and related products due to the presence of pesticide residue. The recall affects all lot numbers of specific items sold in bulk. Consumers are urged to return the products for a full refund.

Cannabis Products and Methods Patent Application

The USPTO has published a patent application (US20260083661A1) for cannabis-based products and methods, including lotions, soaps, perfumes, and teas. The application was filed on October 7, 2025, and lists Lawrence Lanier Long as the inventor.

Oxazolidinone Liposome Compositions with Improved Storage Stability

The USPTO has published a new patent application from Akagera Medicines, Inc. detailing oxazolidinone liposome compositions designed for improved storage stability. The application, filed on December 2, 2025, describes methods for manufacturing and using these compositions.

High-Bioactivity Goat Colostrum Powder Preparation Method

The USPTO has published a patent application detailing a method for preparing a high-bioactivity goat colostrum composite freeze-dried powder. The invention focuses on enhancing the stability and survival rate of probiotics within the powder through encapsulation techniques.

Patent for Spray-Dried Amorphous Solid Dispersions Using Polyvinyl Alcohol

The USPTO has published a new patent application (US20260083676A1) detailing a method for preparing spray-dried amorphous solid dispersions of active pharmaceutical ingredients using polyvinyl alcohol. The application was filed on September 14, 2023, by inventors Lena Mueller, Laura Halstenberg, Thomas Kipping, and Nicole Di Gallo.

Adagrasib Solid Pharmaceutical Compositions for Treating Cancer

The USPTO has published a new patent application (US20260083679A1) detailing solid pharmaceutical compositions containing adagrasib for treating cancer. The application, filed on December 3, 2025, includes methods for manufacturing these compositions and treating cancer.

Protein Nanospheres for Treating Chemotherapy Dysfunction

The USPTO has published a patent application (US20260083683A1) for protein nanospheres designed to treat dysfunction caused by chemotherapy and immunosuppressive therapy. The application details the manufacture and use of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) for mitigating toxic effects of cancer treatments.

Kit for Drug-Containing Nanoparticles and Composition for Drug Delivery

The USPTO has published a new patent application (US20260083682A1) by SAMYANG HOLDINGS CORPORATION for a kit and composition for constructing drug-containing nanoparticles for enhanced drug delivery. The application details a method utilizing cationic compounds and anionic polymers to improve cellular drug delivery efficiency.

Patent Application: Solid Medicinal Forms with Stabilised Active Ingredient

The USPTO has published a new patent application (US20260083677A1) from Astellas Pharma Inc. The application describes solid medicinal forms containing active ingredients stabilized with specific drying agents, aiming for reduced moisture content. This is a new patent filing, not a regulatory rule or guidance.

Patent Application: Spray Dried Lipid Nanoparticle Formulations

The USPTO has published a patent application (US20260083681A1) detailing formulations for spray-dried lipid nanoparticle matrix particles. The application, filed on September 16, 2025, describes a composition including lipid nanoparticles, a buffer system, and a barrier matrix stabilizer. This publication is part of the patent application process and does not represent a final grant or regulatory requirement.

Sunscreen Compositions and Methods of Use

The USPTO has published a patent application from Mary Kay Inc. detailing new sunscreen compositions designed to protect skin from UV radiation. The application describes specific formulations involving film formers and organic UV filters, along with methods of making and using these compositions.

Mesoporous Nano-Magnesium Oxide for Drug Loading

The USPTO has published a patent application for a mesoporous nano-magnesium oxide material designed for drug loading. The application details the material's properties, including particle size and pore structure, and outlines a preparation method involving magnesium oxalate and CTAB.

KAO CORPORATION patent for hair treatment agent

The USPTO has published a patent application by KAO CORPORATION for a hair treatment agent. The application, filed on May 31, 2023, details a specific formulation involving film-forming polymers and organopolysiloxanes.

Oral GLP-1 Compound Dosing Patent Application

The USPTO has published a patent application (US20260083678A1) related to oral dosing of GLP-1 compounds. The application was filed on December 3, 2025, by inventors Flemming S. Nielsen and Per Sauerberg, and relates to improved uses of GLP-1 peptides in oral therapy.

Anti-CTLA-4 Antibody Conjugate Activated by Tumor Microenvironment

The USPTO has published a patent application (US20260085118A1) for a novel conjugate of an anti-CTLA-4 antibody activated by the tumor microenvironment. The application details a dual-activated conjugate designed to improve targeting efficacy, overcome drug resistance, and reduce toxicity.

Anti-GPRC5D Antibody for Cancer Treatment

The USPTO has published a patent application (US20260085114A1) filed by Kyinno Biotechnology Co., Ltd. The application describes an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or fragment thereof for the treatment of tumors or cancers. It also details a bispecific antibody targeting GPRC5D and CD3.

CD3 Binding Antibodies Patent Application Inventors Listed

The USPTO has published a new patent application, US20260085115A1, related to CD3 binding antibodies. The application, filed on June 2, 2025, lists inventors Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, and Duy Pham.

Patent Application: Antibody Heavy Chain Regions Reduce Fc Gamma Receptor Binding

The USPTO has published a patent application (US20260085116A1) detailing antibody heavy chain constant regions modified to reduce binding to Fc gamma receptors. This modification, achieved through specific residue replacements or deletions in the hinge region, aims to decrease effector functions in antibodies and Fc fusion proteins.

Antibodies with chimeric constant domains reduce effector functions

The USPTO has published a patent application (US20260085117A1) detailing antibodies with chimeric constant domains designed to reduce effector functions. The application, filed on November 24, 2025, describes recombinant polypeptides and methods for their production.

Patent Application for Treating Cancer with Anti-CTLA4 Antibodies

The USPTO has published a new patent application (US20260085119A1) from ADAGENE PTE. LTD. for methods of treating cancers using anti-CTLA4 antibodies. The application details compositions and treatment methods, including combination therapies for cancers resistant to PD-1 or PD-L1 inhibitors.

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a new patent application (US20260085120A1) for compositions and methods related to cancer treatment. The application describes binding agents, carrier proteins, and therapeutic agents, particularly for cancers expressing PD-LI or PD-L2, and lyophilized compositions.

Patent Application: Detecting Pancreatic Cancer

The USPTO has published a patent application (US20260085360A1) detailing methods for detecting pancreatic cancer. The application describes a method involving measuring CA19-9 levels alongside other markers like OPN, MIA, and CEACAM-1 in a subject's sample.

DARPIN Compositions for Treating Shiga Toxin Diseases

The USPTO has published a patent application (US20260085097A1) detailing DARPIN-containing compositions for treating Shiga toxin diseases. The application highlights the thermostability and high microbial expression yield of DARPin as advantages over antibody therapeutics.

Patent Application: Method for Acute Respiratory Distress Syndrome Treatment

The USPTO has published a new patent application (US20260085098A1) from Revolo Biotherapeutics Limited for a method to treat acute respiratory distress syndrome. The application details a treatment method involving the administration of a specific peptide molecule during or in response to a relapse to induce remission.

Process for Isolating Osteopontin and Glycomacropeptide from Whey

The USPTO has published a new patent application (US20260085099A1) detailing a process for isolating osteopontin (OPN) and glycomacropeptide (GMP) from whey. The application, filed on September 15, 2023, describes a chromatography-based method for purification.

Patent Application: Tumor Targeting Methods and Reagents

The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.

Patent Application for Genome Editing Compositions and Methods

The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.

CRISPR Methods Targeting CD70 Expression for Engineered Cells

The USPTO has published a patent application (US20260083861A1) filed by Editas Medicine, Inc. The application describes CRISPR-related systems and methods for targeting the CD70 gene expression in engineered cells, particularly T cells, for potential therapeutic applications.

Patent Application: Treating Brain Diseases with rAAV Particles

The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.

Patent Application for Contrast Agents in Diagnostic Imaging

The USPTO has published a patent application (US20260083864A1) for a new class of compounds intended for use as contrast agents in diagnostic imaging, including computed tomography (CT) and magnetic resonance imaging (MRI). The application details specific compound formulas, metal chelates, and preparation methods.